Cybin 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  psilocybin sublingual (CYB001) / Cybin
    Enrollment closed:  Comparing the Effects of Psilocin and Psilocybin in Healthy Adults (clinicaltrials.gov) -  Sep 24, 2024   
    P1,  N=20, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
  • ||||||||||  dimethyltryptamine (SPL026) / Cybin
    Clinical, P1 data, PK/PD data, Journal:  Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial. (Pubmed Central) -  Jan 26, 2024   
    P1/2
    Using the analysis of the safety, tolerability, PD, PK results, doses of 21.5?mg SPL026 were the most likely to provide an intense, tolerated experience. Based on the data obtained from this part of the trial, a dose of 21.5?mg SPL026 given as a 2-phase IV infusion over 10?min (6?mg/5?min and 15.5?mg/5?min) was selected as the dose to be taken into patients in Part B (to be presented in a future manuscript).Clinical trial registration:www.clinicaltrials.gov, identifier NCT04673383; https://www.clinicaltrialsregister.eu, identifier 2020-000251-13; https://www.isrctn.com/, identifier ISRCTN63465876.
  • ||||||||||  psilocybin sublingual (CYB001) / Cybin
    Trial completion date, Trial primary completion date:  Comparing the Effects of Psilocin and Psilocybin in Healthy Adults (clinicaltrials.gov) -  Dec 15, 2023   
    P1,  N=20, Recruiting, 
    Based on the data obtained from this part of the trial, a dose of 21.5?mg SPL026 given as a 2-phase IV infusion over 10?min (6?mg/5?min and 15.5?mg/5?min) was selected as the dose to be taken into patients in Part B (to be presented in a future manuscript).Clinical trial registration:www.clinicaltrials.gov, identifier NCT04673383; https://www.clinicaltrialsregister.eu, identifier 2020-000251-13; https://www.isrctn.com/, identifier ISRCTN63465876. Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Dec 2024 --> Mar 2025
  • ||||||||||  dimethyltryptamine (SPL026) / Cybin
    Trial completion, Combination therapy:  SPL026 With or Without SSRIs in Participants With MDD (clinicaltrials.gov) -  Aug 14, 2023   
    P1,  N=18, Completed, 
    Trial completion date: Oct 2023 --> Jan 2024 Active, not recruiting --> Completed
  • ||||||||||  dimethyltryptamine (SPL026) / Cybin
    Enrollment closed, Trial primary completion date, Combination therapy:  SPL026 With or Without SSRIs in Participants With MDD (clinicaltrials.gov) -  Jul 5, 2023   
    P1,  N=19, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: May 2023 --> Aug 2023
  • ||||||||||  dimethyltryptamine (SPL026) / Cybin
    Trial completion:  IM and IV SPL026 Drug Product in Healthy Participants (clinicaltrials.gov) -  Jul 5, 2023   
    P1,  N=14, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: May 2023 --> Aug 2023 Active, not recruiting --> Completed
  • ||||||||||  dimethyltryptamine (SPL026) / Cybin
    Enrollment closed:  IM and IV SPL026 Drug Product in Healthy Participants (clinicaltrials.gov) -  Apr 18, 2023   
    P1,  N=14, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  dimethyltryptamine (SPL026) / Cybin
    Trial completion date, Trial primary completion date:  IM and IV SPL026 Drug Product in Healthy Participants (clinicaltrials.gov) -  Apr 12, 2023   
    P1,  N=14, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Mar 2023 --> Jun 2023
  • ||||||||||  dimethyltryptamine (SPL026) / Cybin
    Enrollment open:  IM and IV SPL026 Drug Product in Healthy Participants (clinicaltrials.gov) -  Jan 20, 2023   
    P1,  N=14, Recruiting, 
    N=40 --> 68 Not yet recruiting --> Recruiting
  • ||||||||||  dimethyltryptamine (SPL026) / Cybin
    Trial completion:  SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients (clinicaltrials.gov) -  Jan 4, 2023   
    P1/2,  N=66, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  deuterated psilocybin analog (CYB003) / Cybin
    CYB003: A novel, orally active analog of psilocybin for the potential treatment of Major Depressive Disorder (SDCC Halls B-H) -  Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_3479;    
    These findings suggest that, compared to psilocybin, CYB003 may provide therapeutic benefit but across a shorter clinical visit and with improved dosing accuracy, resulting in improved tolerability. Based on these preclinical studies, CYB003 will progress into Phase 1/2a clinical studies in 2022.
  • ||||||||||  dimethyltryptamine (SPL026) / Cybin
    Enrollment closed:  SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients (clinicaltrials.gov) -  Sep 23, 2022   
    P1/2,  N=66, Active, not recruiting, 
    Based on these preclinical studies, CYB003 will progress into Phase 1/2a clinical studies in 2022. Recruiting --> Active, not recruiting
  • ||||||||||  dimethyltryptamine (SPL026) / Cybin
    Enrollment open:  SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients (clinicaltrials.gov) -  Feb 20, 2021   
    P1/2,  N=68, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting